DARATUMUMAB and PNEUMONIA

Overview

PNEUMONIA is the #4 most commonly reported adverse reaction for DARATUMUMAB, manufactured by Janssen Biotech, Inc.. There are 1,921 FDA adverse event reports linking DARATUMUMAB to PNEUMONIA. This represents approximately 3.2% of all 59,976 adverse event reports for this drug.

Patients taking DARATUMUMAB who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PNEUMONIA is moderately reported among DARATUMUMAB users, representing a notable but not dominant share of adverse events.

Other Side Effects of DARATUMUMAB

In addition to pneumonia, the following adverse reactions have been reported for DARATUMUMAB:

• PLASMA CELL MYELOMA — 3,705 reports
• OFF LABEL USE — 3,306 reports
• INFUSION RELATED REACTION — 2,597 reports
• NEUTROPENIA — 1,848 reports
• FATIGUE — 1,683 reports
• DIARRHOEA — 1,639 reports
• DRUG INEFFECTIVE — 1,469 reports
• DEATH — 1,418 reports
• NEUROPATHY PERIPHERAL — 1,391 reports
• THROMBOCYTOPENIA — 1,327 reports

Other Drugs Associated with PNEUMONIA

The following drugs have also been linked to pneumonia in FDA adverse event reports:

Does DARATUMUMAB cause PNEUMONIA?

PNEUMONIA has been reported as an adverse event in 1,921 FDA reports for DARATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PNEUMONIA with DARATUMUMAB?

PNEUMONIA accounts for approximately 3.2% of all adverse event reports for DARATUMUMAB, making it a notable side effect.

What should I do if I experience PNEUMONIA while taking DARATUMUMAB?

If you experience pneumonia while taking DARATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages